Weight Loss & Metabolic Health

What This Article Covers

• What the STEP 4 clinical trial was about
• How semaglutide helped people maintain weight loss
• What happened when participants stopped taking the medication
• Effects on blood sugar, cholesterol, and waist size
• What this study means (and doesn’t mean) for everyday people
• Where the research is headed next

Quick Summary (TL;DR)

A major clinical trial showed that people who kept using semaglutide (a GLP-1 weight loss medicine) continued to lose weight, while those who stopped regained some. It highlights the importance of sustained use for long-term weight maintenance.

What the Scientists Studied

What They Found (And What It Means)

Continued Treatment = Continued Weight Loss

• Semaglutide users lost an extra 7.9% body weight
• Placebo users gained 6.9%
• Total difference: −14.8% in weight between groups

Other Benefits Seen

• Waist circumference got smaller with semaglutide
• Blood sugar and cholesterol levels improved
• Blood pressure stayed stable
• Physical function scores improved

Think of It Like This…

If your body’s a balloon, semaglutide helps let the air out — and keeps it from filling back up.

What This Doesn’t Mean (Keeping It Honest)

This Study Doesn’t Prove…

• That semaglutide works forever
• That it’s safe for all people or long-term
• That it works without lifestyle changes
• That it’s a cure for obesity

It’s a tool, not a miracle. Real-world results may vary.

How This Might Help You (Without Making Claims)

Researchers are asking:

• What happens after several years on semaglutide?
• Can it be tapered off safely?
• Who benefits most — and how long should they stay on it?
• How can we make it more affordable and accessible?

Conclusion

Explore More Medical Breakthroughs

Scientific Source

JAMA – View Full Study
Rubino D, Abrahamsson N, Davies M, et al; STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1421–1432. doi:10.1001/jama.2021.19896

What This Article Covers

– How tirzepatide (Zepbound) and semaglutide (Wegovy) work
– What scientists discovered in a 72-week head-to-head trial
– How much weight real people lost with each drug
– Why obesity matters and how it impacts everyday life
– Honest truths about what this study does and doesn’t prove
– The future of obesity treatment and what might come next

Quick Summary (TL;DR)

Doctors tested two powerful weight-loss medications — tirzepatide and semaglutide — to see which helped people shed more pounds. Over 72 weeks, tirzepatide helped people lose an average of 20% of their body weight, compared to 13.7% with semaglutide. The findings could shift how obesity is treated around the world.

Why This Topic Matters Right Now

The world is facing a health challenge: **obesity**.

More than 1 in 3 adults in the U.S. are obese. That’s not just about how someone looks — it’s about their health and future. Obesity raises the risk of serious problems like heart disease, type 2 diabetes, certain cancers, stroke, and even depression.

Many people try to lose weight — sometimes over and over — but with limited success. Some feel trapped in a cycle of gaining and losing without real progress. This leads to frustration, fatigue, and shame.

Now, two medications — semaglutide (Wegovy) and tirzepatide (Zepbound) — are offering something new. They don't rely on willpower alone. They work with the body’s hormones to reduce hunger and promote fullness.

So the question becomes: **which one works better?**

How Obesity Affects Daily Life

It’s not just the number on the scale. Obesity touches nearly every part of a person’s life:

– **Climbing stairs** feels like hiking a mountain.
– **Tying shoes** can leave someone short of breath.
– **Sleep** becomes restless due to conditions like sleep apnea.
– **Pain** shows up in the knees, back, and feet from carrying extra weight.
– **Social situations** feel awkward or avoidable due to body image struggles.
– **Doctors’ appointments** often become reminders of failure.

For many, obesity isn’t a lack of effort — it’s a result of biology, environment, and emotional patterns built over years. Medications like tirzepatide and semaglutide give people a biological “reset” button — a new starting line.

What the Scientists Studied

In a clinical trial published in the *New England Journal of Medicine*, researchers designed a head-to-head test. Think of it like a health science version of a championship match.

They enrolled **751 adults with obesity** (no diabetes) and randomly assigned them to take either:
– **Tirzepatide (Zepbound)** or
– **Semaglutide (Wegovy)**

Every participant received weekly injections over a period of **72 weeks** — almost a year and a half. Importantly, everyone followed the same lifestyle guidance, including basic diet and activity support. No crash diets, no extreme boot camps — just consistent use of the medication.

The scientists tracked:
– Total weight lost
– How many people lost ≥15%, ≥20%, or ≥25% of their body weight
– Side effects
– Adherence to treatment (how often people stuck with it)

How the Drugs Work (In Everyday Language)

To understand the results, let’s talk about how the medications actually work.

**Semaglutide (Wegovy):**
– Acts like a hormone called GLP-1.
– GLP-1 tells your brain, “I’m full!” after you eat.
– It also slows down how quickly food leaves your stomach, so you stay fuller longer.
– The result: you eat less without feeling like you're starving.

**Tirzepatide (Zepbound):**
– Acts like GLP-1 **and** another hormone called GIP.
– GIP boosts insulin response and may work even better when combined with GLP-1.
– It’s like giving your body **two gears instead of one** for appetite and sugar control.

Imagine your hunger hormones as the thermostat in your house. These drugs help **reset the thermostat** so you're no longer always “running hot” with cravings or excessive hunger.

What They Found (And What It Means)

After 72 weeks, here’s what the researchers discovered:

– **Tirzepatide group:** Average weight loss of **20.2%**
– **Semaglutide group:** Average weight loss of **13.7%**

To put that into perspective, imagine two people both weighing 250 pounds at the start:
– On tirzepatide: they lose about **50 pounds**
– On semaglutide: they lose about **34 pounds**

That’s a **16-pound difference** — more than a full bowling ball!

Now let’s look at how many participants hit certain weight loss goals:

✅ **25%+ weight loss:**
– Tirzepatide: **57% of people**
– Semaglutide: **28% of people**

✅ **20%+ weight loss:**
– Tirzepatide: **69%**
– Semaglutide: **42%**

✅ **15%+ weight loss:**
– Tirzepatide: **80%**
– Semaglutide: **65%**

These aren’t small numbers. This is a real shift in what’s possible.

What This Doesn’t Mean (Why We Still Need Caution)

As exciting as this is, we need to be honest.

❗ **It doesn’t mean everyone will see these results.** Some people may lose more, others less. Everyone’s body is different.

❗ **It doesn’t mean tirzepatide is safer or better overall.** The study focused on weight loss — not long-term safety, heart health, or mental health impacts.

❗ **It doesn’t replace healthy habits.** These drugs are tools, not magic wands. Eating nutritious foods, moving your body, and sleeping well still matter.

❗ **It doesn’t include people with diabetes.** The study only looked at those without diabetes, so results may differ in diabetic populations.

In short: tirzepatide looks more effective for weight loss — **but it’s not a one-size-fits-all solution.**

Side Effects: What to Watch For

Both medications had side effects, most related to digestion. These included:
– Nausea
– Diarrhea
– Vomiting
– Constipation
– Indigestion

These issues were usually mild to moderate. But for some, they were enough to stop treatment. Your doctor will help weigh risks vs. benefits.

Real People, Real Results (Sarah's Story)

Let’s bring this study to life with a story.

Meet **Sarah**. She’s 42, weighs 245 pounds, and has been battling obesity for most of her adult life. She’s tried it all:
– Fad diets
– Gym memberships
– Intermittent fasting
– Food tracking apps

Nothing sticks. And every failed attempt chips away at her confidence.

Sarah's doctor recommends she consider medical support. Together, they look at two options: semaglutide and tirzepatide.

Sarah wants to lose weight, but she also wants to:
– Ease her joint pain
– Get off her sleep apnea machine
– Play with her kids without losing her breath
– Feel confident in photos again

She starts on tirzepatide. Over a year, she loses 52 pounds. Her knees feel better. Her energy returns. And for the first time in years, **she feels in control**.

This isn’t just about weight — it’s about freedom, energy, and dignity.

How This Might Help You

If you’re someone who’s struggled with weight for years, this study shows something important: **You are not alone, and your body isn’t broken.**

Science is evolving. Doctors now have better tools to help support your journey.

You don’t have to “try harder.” You just need the right tools, guidance, and patience.

Talk to your healthcare provider about whether medications like tirzepatide or semaglutide are safe and appropriate for you. This is about creating a life where health feels possible again.

Where the Science Goes Next

This study opens doors, but it’s only the beginning.

Researchers still want to explore:
– How long the weight stays off after stopping the drugs
– How the drugs work in people with **type 2 diabetes**
– The impact on heart disease, cholesterol, and inflammation
– Whether the medications help reduce cancer or arthritis risk
– How to make access more affordable for more people

Imagine a world where:
– Obesity is managed like any other health condition
– People get support early — not after damage is done
– Food, medicine, and lifestyle all work together to heal the body

That’s where we’re heading.

Conclusion

This head-to-head trial shows that **tirzepatide outperforms semaglutide in weight loss results** for people with obesity. Nearly twice as many people hit the 25% weight-loss mark.

But both medications represent a breakthrough in treating a condition that affects millions. They're more than weight loss tools — they’re **hope in a syringe**.

Obesity doesn’t have to be a life sentence. With science, compassion, and honesty, we can finally offer people the chance to feel good in their own bodies again.

Explore More Medical Breakthroughs

Explore More Medical Breakthroughs

Why Muscle Loss During Weight Loss Matters

Millions of people are using semaglutide-based medications like Ozempic or Wegovy to lose weight. But what many don’t realize is this: up to 35% of the weight lost may come from muscle, not just fat.

Muscle is critical for everyday strength, bone health, metabolism, and energy. When you lose too much muscle, you may feel weaker, get tired faster, and even slow down your metabolism — making it harder to keep the weight off long term.

That’s why scientists at Regeneron launched the COURAGE trial — to test if combining semaglutide with another medication could help people keep their strength while losing weight.

What Is Semaglutide and How Does It Work?

Semaglutide is part of a group of medicines called GLP-1 receptor agonists. Here’s what that means in plain English:

When you eat, your body releases a hormone called GLP-1. It tells your brain: “You’re full!” Semaglutide mimics that hormone. It helps people:

• Feel full faster

• Eat less

• Lose weight more easily

It’s like having a louder voice inside your brain saying, “I’m satisfied, no need for more.”

While powerful for fat loss, semaglutide isn’t picky. It causes the body to lose both fat and muscle. That’s where this new study comes in.

Introducing Trevogrumab: The Muscle Guardian

Trevogrumab is a special kind of medicine that blocks myostatin, a protein that slows down muscle growth. Think of myostatin like a “muscle brake” — it tells your body to stop building muscle.

When trevogrumab blocks that brake, your body is allowed to:

• Keep more muscle during weight loss

• Possibly rebuild strength even while slimming down

In the COURAGE trial, researchers combined semaglutide + trevogrumab, and in some cases added a third drug called garetosmab (which blocks another growth-limiting protein called activin A).

Inside the COURAGE Trial: What Did the Scientists Do?

Here’s what the study involved:

• People with obesity joined the trial and received semaglutide.

• Some also got trevogrumab, with or without garetosmab.

• Scientists measured what type of weight was lost — fat or muscle — over time.

The goal? See if trevogrumab could protect lean muscle mass while semaglutide helped people lose fat.

And the early results? Promising.

What They Found: Less Muscle Loss, More Fat Loss

Participants who received just semaglutide lost weight — but around 35% of that was muscle.

However, when semaglutide was paired with trevogrumab, researchers saw:

• More fat loss

• Much less muscle loss

• 50% to 80% of the usual lean mass loss was prevented

In simple terms: the medicine combo allowed people to lose the weight they wanted, but keep more of their strength and energy.

Why This Could Be a Game Changer

Losing weight is hard. Keeping it off is harder. And if you lose too much muscle along the way, it can hurt your body instead of helping it.

This study shows a possible new path:

• A treatment that targets fat loss

• While preserving muscle strength

• With the potential to improve long-term health outcomes

This could be especially useful for older adults, athletes recovering from weight gain, or anyone wanting to avoid weakness or fatigue during weight loss.

Is This Available Now? What You Need to Know

Not yet.

This was an interim result from a Phase 2 trial — meaning it's halfway through a multi-stage study. The drugs (trevogrumab and garetosmab) are not approved for public use yet.

Here’s what we still don’t know:

• Will this combo work long-term?

• Is it safe for all types of people?

• Will it be affordable or covered by insurance?

• Are there side effects we haven’t seen yet?

That’s why scientists are continuing the trial — to answer these important questions.

What You Can Do Today to Protect Your Muscle

Even without new medications, there are simple ways to keep your muscle while losing fat:

•  Lift weights or do bodyweight exercises

•  Eat enough protein (like eggs, chicken, beans, and nuts)

•  Get plenty of rest and sleep

•  Stay active with daily walking or movement

These strategies help signal to your body: “Keep the muscle, just burn the fat.”

What’s Next for This Research?

The COURAGE trial will continue collecting data. Scientists will be looking at:

• More people with different backgrounds

• Long-term effects of the drug combo

• Safety, muscle performance, and weight maintenance

• Potential for FDA review and approval

If the results keep trending upward, this could become the future of obesity treatment — helping people lose weight without feeling weak or tired.

Final Thoughts: A Hopeful Path Ahead

Losing weight is about more than just the number on the scale. It’s about staying strong, feeling good, and protecting your health.

This study offers a new option — a possible future where you don’t have to trade strength for slimness.

Semaglutide has already changed the way we approach obesity. With new support from drugs like trevogrumab, we might be looking at a new chapter in medicine — one where your body can hold on to what matters most while shedding the rest.

Explore More Medical Breakthroughs

To learn more about exciting developments in the medical field, explore more medical breakthroughs at Meridian Medical Centre.

What This Article Covers

• Understanding Obesity and Its Challenges
• What is MariTide?
• How the Study Was Conducted
• Key Findings and Their Importance
• What the Study Doesn’t Prove
• Future Directions for Obesity Treatments

Quick Summary (TL;DR)

In a recent study, a new monthly obesity injection called MariTide helped people lose about 20% of their body weight over a year. This is a big deal because it gives folks an easier option for managing obesity, a condition that affects many people today.

Why This Topic Matters Right Now

Obesity is a growing problem around the world. Many people struggle with their weight, which can lead to serious health issues like diabetes and heart disease. It’s not just about looking good; it’s about feeling good and staying healthy! With new treatments like MariTide, there’s hope for better weight management options for those who need them.

What the Scientists Studied

Let’s imagine you and your friends are in a race, but this is not just any race. It’s a race against weight! Scientists wanted to find out if a new drug called MariTide could help people lose weight more easily. They gathered a group of nearly 600 adults who either had obesity or obesity along with type 2 diabetes. They divided these adults into two teams: one team got the monthly injection of MariTide, while the other team received a placebo, which is like getting a fake medicine that doesn’t actually do anything.

The scientists wanted to see how much weight the participants would lose after a whole year. They also looked at other important health markers, like blood sugar levels, which is super important for people with diabetes.

What They Found (And What It Means)

After a year of taking MariTide, the participants who received the injection lost an average of 20% of their body weight. That’s like if you weighed 100 pounds and lost 20 pounds! The placebo group, on the other hand, lost only about 2.6% of their weight. Imagine being in a race where one team runs super fast while the other barely moves.

For people with diabetes who took MariTide, they lost about 17% of their body weight compared to only 1.4% for those who didn’t get the injection. Similarly, MariTide also helped lower the blood sugar levels of participants, which is crucial for managing diabetes.

What’s surprising is that even after a year, the participants who took MariTide were still losing weight. This suggests that if they keep taking it, they might continue to lose even more weight over time!

What This Doesn’t Mean (Keeping It Honest)

Now, it’s important to know what this study doesn’t prove. Just because some people lost weight with MariTide doesn’t mean it will work for everyone. Weight loss can be tricky, and many factors affect it, like diet, exercise, and individual health conditions. So while the results are promising, they don’t guarantee success for every person who tries it.

How This Might Help You (Without Making Claims)

So, how does this all connect to you? Well, if you or someone you know struggles with weight, knowing that there are new options out there can be encouraging. It shows that science is working hard to find better ways to help people. Staying hopeful and informed about new treatments can empower you to have better conversations with doctors about weight management.

Where the Science Goes Next

The researchers are not stopping here! The next step is to conduct a phase 3 trial, which is like the final exam for the drug before it can be approved for everyone to use. This trial will last for 72 weeks and will help scientists learn more about how effective MariTide is over a longer time.

There’s also talk of testing the drug for every-other-month doses. If that works, it could be even more convenient for patients who don’t want to think about taking a shot every month.

Conclusion

In summary, the new monthly injection called MariTide has shown great promise in helping people with obesity lose weight. With an average weight loss of about 20%, it provides a new option for those struggling with their weight. As scientists continue to study this drug, it opens the door for more effective treatments in the future.

Explore More Medical Breakthroughs

Discover other exciting medical advancements and how they can impact health and wellness by visiting Explore More Medical Breakthroughs.

Understanding Obesity and Its Challenges

Obesity is like carrying around too many backpacks filled with heavy books. When you have too much weight, it can slow you down and make it harder to enjoy activities like playing outside or running. It can also lead to health problems, just like how carrying too many backpacks can hurt your back.

Many people face challenges when trying to lose weight. They might feel tired, hungry, or even discouraged. That’s why finding new ways to help manage weight is so important!

What is MariTide?

MariTide is a special medicine that scientists have developed to help people lose weight. It's like a superhero in a syringe! Instead of taking a shot every week, which can feel like a chore, people can take MariTide just once a month. This makes it easier for those who have busy lives or who are already taking other medications.

But how does MariTide work? It’s a type of drug called a monoclonal antibody. Don’t let the big words scare you! Think of it like a special key that unlocks pathways in your body to help you lose weight. It helps your body control hunger and how much food you eat, making it easier to maintain a healthy weight.

How the Study Was Conducted

To see if MariTide really works, researchers set up a big experiment. They gathered almost 600 adults, which is like filling a whole classroom with students. Some of these adults had obesity alone, while others had obesity along with type 2 diabetes.

The participants were split into two groups, almost like two teams in a sports game. One team got the MariTide shot once a month, while the other team received a placebo shot, which is just a fake shot that doesn’t help.

The scientists checked on the participants regularly, like a coach checking on their players to see how they were doing. They wanted to know how much weight everyone lost and if there were any side effects.

Key Findings and Their Importance

After a year, the results were exciting! The team that took MariTide lost an average of 20% of their body weight, while the placebo team lost only about 2.6%. That’s like comparing a cheetah running at full speed to a turtle taking its time!

These results are important because they show that a monthly injection can really make a difference in weight loss. For people with type 2 diabetes, the average weight loss was about 17%. This could lead to better health outcomes for those individuals, reducing their risk of serious health conditions.

What This Doesn’t Mean (Keeping It Honest)

While the results are promising, it’s essential to understand that this doesn’t mean everyone will lose weight with MariTide. Just like in sports, not every player will win every time. Each person’s body is different, and what works for one person might not work for another.

It’s also important to remember that losing weight isn’t just about taking a medicine. Eating healthy foods and being active are crucial parts of the journey too. MariTide is just one tool that could help in that journey.

Future Directions for Obesity Treatments

The journey of MariTide doesn’t end here. Scientists are excited to keep exploring how this drug can help people. They plan to conduct more studies to gather additional information. This is like preparing for a big test; they want to be sure they understand everything before making it available to everyone.

Additionally, researchers are looking into the possibility of taking MariTide every other month. If this works, it could be even easier for people to manage their weight without the hassle of frequent injections.

In the future, we may see even more treatments for obesity, which means more options for people who struggle with weight management.

Conclusion

In conclusion, the new monthly obesity injection MariTide has shown amazing potential in helping people lose weight. With its ability to provide an average loss of 20% over a year, it could be a game-changer for those facing obesity. As research continues, there is hope for more effective treatments in the future.

By understanding these developments, we can stay informed and hopeful about the future of health and wellness.

What This Article Covers

• A closer look at how the HRS9531 shot works inside your body
• What GLP-1 and GIP hormones are and why scientists love them
• Surprising results from Hengrui’s Phase III clinical trial
• How this new shot compares to popular drugs like Ozempic and Wegovy
• The bigger picture: obesity in China and worldwide
• Honest discussion on what the drug can’t promise yet
• Where science and drug development go from here

Quick Summary (TL;DR)

In a major new study out of China, a weekly injection developed by Hengrui Pharmaceuticals—called HRS9531—helped people lose an average of 17.7% of their body weight over 48 weeks. That’s one of the biggest reductions ever seen in a Phase III trial for a weight loss drug. The medication works by copying two important gut hormones (GLP-1 and GIP), helping people feel full longer, curb hunger, and reduce fat storage. It could mark a turning point for obesity treatment—especially in Asia.

Why This Topic Matters Right Now

We’re living in the middle of what many doctors call a “global weight crisis.” More than 2 billion people around the world are overweight, and about 650 million are considered obese. These numbers have tripled since 1975. In China alone, over 50% of adults are overweight or obese—and that number keeps rising.

Obesity isn’t just about how people look. It raises the risk of many health problems:

Type 2 diabetes

• High blood pressure
• Heart disease and stroke
• Sleep apnea
• Depression and anxiety
• Even certain cancers

The problem is huge—but so is the opportunity for solutions. Traditional weight loss strategies like dieting and exercise work for some people, but many struggle to maintain results long-term. That’s where new medicines like GLP-1 receptor agonists come in, offering a science-backed way to tackle appetite and fat storage at the hormone level.

What the Scientists Studied

Let’s take a step back and understand what happened in this new study—and why it’s getting so much attention.

Imagine your body is like a car. When it’s working well, it burns the right amount of fuel (calories), uses energy efficiently, and tells you when the gas tank (your stomach) is full. But for many people, that system starts misfiring. You might feel hungry all the time, even when you’ve eaten enough. Or your body might store too much of your food as fat instead of using it for energy.

Scientists have learned that certain hormones in your gut help regulate these signals. Two key ones are:

GLP-1 (glucagon-like peptide-1): This hormone tells your brain you’re full, slows down digestion, and helps balance blood sugar.

GIP (glucose-dependent insulinotropic polypeptide): This hormone helps the body handle sugar and fat after eating, and may also help reduce appetite when paired with GLP-1.

Hengrui’s new drug, HRS9531, is a “dual agonist”—meaning it activates both GLP-1 and GIP receptors in the body. Think of it like flipping two switches instead of one to help regulate hunger and metabolism.

In this study, 567 adults in China who were overweight or obese (but didn’t have diabetes) were randomly divided into two groups:

One group got a weekly injection of HRS9531

The other got a placebo shot

The study lasted 48 weeks, nearly one full year. Everyone was monitored closely—doctors tracked weight, appetite, blood markers, and side effects.

What They Found (And What It Means)

The results were nothing short of impressive.

People taking HRS9531 lost 17.7% more body weight than the placebo group.

That means someone who started at 200 pounds could lose over 35 pounds on average.

88% of participants lost at least 5% of their body weight (a level often linked to better health outcomes).

44.4% of participants lost 20% or more of their body weight—a level that rivals or exceeds bariatric surgery for some people.

But these aren’t just numbers—they represent real changes in how people live and feel. Losing even 5% of body weight can improve:

• Insulin sensitivity
• Blood pressure
• Cholesterol levels
• Joint pain
• Sleep quality

And for people who’ve struggled with diets that didn’t work, these medications provide a sense of relief—like finally having a “reset button” for appetite and cravings.

How It Works, in Simple Terms

Let’s picture this through a simple story.

You’re walking through your day with a pair of invisible headphones. These headphones are constantly playing messages from your gut to your brain: “Eat now,” “You’re still hungry,” “That cookie looks really good…”

For people with obesity, those messages can be loud, distorted, and constant—even after eating. GLP-1 and GIP-based drugs help quiet that noise. They gently turn down the volume, so your brain hears the true signals from your stomach: “You’ve had enough,” or “Wait, you’re not really hungry.”

At the same time, these drugs help your body burn calories more efficiently and stop storing excess energy as belly fat.

What This Doesn’t Mean (Keeping It Honest)

While the study was exciting, it’s important to stay grounded.

Here’s what this trial doesn’t prove yet:

Long-term results: We don’t know if people will keep the weight off after stopping the drug.

Diabetes impact: The study excluded people with Type 2 diabetes, so results may differ in that group.

Side effects: While most were mild, some people reported nausea, vomiting, and diarrhea—common issues with GLP-1 drugs.

Real-world use: Clinical trials are tightly controlled. We don’t yet know how this will work in everyday life, outside a research setting.

Not a magic solution: This is a tool—not a replacement for healthy eating, movement, and emotional support.

How This Might Help You (Without Making Claims)

If you’ve ever tried to lose weight and hit a wall, you’re not alone. Willpower isn’t always enough—because your biology plays a huge role in hunger, energy use, and fat storage.

Drugs like HRS9531 work with your body, not against it. They help people feel more in control of their hunger and food choices. Imagine being able to pass on seconds without feeling like you’re starving. Or enjoying a meal without guilt or food noise in your head.

This doesn’t mean everyone should run out and ask for a prescription. But it does mean science is catching up to what people have known all along: weight struggles are complex. And now we have tools that match that complexity—with real potential to help.

How HRS9531 Compares to Wegovy and Mounjaro

It’s natural to wonder: how does this new shot compare to big names like Ozempic, Wegovy (semaglutide), or Mounjaro (tirzepatide)?

Here’s a quick breakdown:

Drug Name Type Weight Loss (avg) FDA Approval
HRS9531 (Hengrui) GLP-1 + GIP 17.7% (in Phase III) Not yet (China-focused)
Semaglutide (Wegovy) GLP-1 ~15% (in trials) Yes
Tirzepatide (Zepbound) GLP-1 + GIP ~22.5% (in SURMOUNT-1) Yes

HRS9531 seems to land between Wegovy and Zepbound in terms of weight loss, based on this trial. But keep in mind:

Populations vary (Chinese adults vs. mostly Western populations)

Dosages and delivery methods may differ

Hengrui may still adjust the formulation or test more doses

Still, it’s promising to see this kind of result from a company outside the U.S.—it suggests we’re entering a global era of obesity treatment innovation.

Where the Science Goes Next

This study was just the beginning for Hengrui. They’ll need:

Larger studies (more diverse participants)

Studies in people with diabetes and other metabolic conditions

Safety trials over multiple years

Comparisons to existing drugs (head-to-head testing)

Potential approval from regulatory agencies like the China NMPA or U.S. FDA

If all goes well, HRS9531 could become one of the top players in the growing obesity drug market—projected to reach $100 billion globally by 2030.

Conclusion

In plain terms: Hengrui’s new weight-loss shot helped people shed nearly one-fifth of their body weight in under a year. It works by mimicking hormones that tell your brain, “You’re full,” and your body, “Let’s burn fat.”

This isn’t just another diet fad—it’s a glimpse into the future of medicine. One that treats obesity with the same seriousness and science we give to other chronic diseases.

While more research is needed, and the drug isn’t yet approved outside of trials, the results are clear: when science targets the brain-gut connection, big changes can happen.

Explore More Medical Breakthroughs

Explore More Medical Breakthroughs

What This Article Covers

• What GLP-1 receptor agonists are and how they work
• Why adults with overweight or obesity start and stop using them
• Key study findings on discontinuation and reinitiation rates
• Real-life reasons behind these patterns like weight loss, side effects, and income
• How these insights may shape future obesity care and drug access

Quick Summary (TL;DR)

A major new study found that many adults who start GLP-1 receptor agonists — a medicine that helps with weight loss — stop using it within a year. Almost half of people with type 2 diabetes and nearly two-thirds without it quit the drug. Some later restarted, especially if they gained weight again. This shows that sticking with these medicines is hard for many people.

Why This Topic Matters Right Now

Right now, millions of people are turning to new weight loss medications like GLP-1 receptor agonists (GLP-1 RAs), such as Ozempic, Wegovy, and others. These drugs are often seen as game-changers for people with obesity or type 2 diabetes. But here’s the problem: a lot of people start these medications and then stop — and many don’t go back on them.

Why is that happening? Is it because of side effects, cost, or something else? This study helps us understand the real-life story behind the stop-and-go use of these powerful treatments.

What the Scientists Studied

Let’s imagine you’ve joined a gym. You start off strong, go every day, feel better — but after a few months, you stop going. Life gets busy, you get sore, or it just gets too expensive. Later, you might try again.

Now imagine that story, but instead of a gym, it’s a medicine meant to help you lose weight and improve your health.

Researchers at JAMA Network Open wanted to understand a similar pattern: why do people who begin taking GLP-1 RAs (a kind of shot or pill that helps manage weight and blood sugar) stop using them — and what makes some of them restart later?

To find out, they looked at 125,474 adults across the U.S. who started these medications between 2017 and 2021. Some had type 2 diabetes, others didn’t. The scientists tracked:

• Who stopped using the medicine within a year
• Who started taking it again
• What made people stop or restart

What They Found (And What It Means)

Here’s what surprised many people:

• Almost half (46.5%) of people with type 2 diabetes stopped the medicine within a year
• Nearly two-thirds (64.8%) without diabetes also stopped
• For those who stopped, about half with diabetes restarted, but only 1 in 3 without diabetes did

Why did they stop?

The study uncovered 3 big reasons:

1. They lost weight – and thought they didn’t need it anymore
2. They had side effects – like nausea or tummy troubles
3. They couldn’t afford it – higher-income people were more likely to stay on it

And why did they come back?

Simple: they gained the weight back. That was one of the strongest reasons people restarted GLP-1 RAs.

Think of it this way:
It's like stopping a diet once you've lost weight, only to find the pounds sneak back. You return to what worked before — if you can afford it.

What This Doesn’t Mean (Keeping It Honest)

Let’s be clear about what the study doesn’t say:

• It doesn’t mean GLP-1 receptor agonists don’t work. They do, especially for weight loss and diabetes control.
• It doesn’t mean stopping is always bad — some people may no longer need the medicine after real lifestyle changes.
• And it doesn’t mean people are doing something wrong. Health care, side effects, and life situations all play a big role.

This is more about understanding real-life challenges, not blaming anyone.

How This Might Help You (Without Making Claims)

This research shines a light on how hard it can be to stay on a long-term weight or diabetes treatment plan — even if the medication is helpful.

If you’re someone considering or currently using GLP-1 RAs, it may help to:

• Know that others go through ups and downs too
• Understand that side effects and cost are very real issues
• Realize that it’s common to need more than one try

You’re not alone — and this science proves it.

Where the Science Goes Next

Now that we know many people are stopping and restarting GLP-1 RA therapy, scientists and doctors are asking:

• How can we help people stick with the treatment, especially when it works?
• Can doctors and insurance companies do more to make access easier?
• What support do people need when they lose weight but want to keep it off — with or without the medicine?

We might also see new ways to combine GLP-1 RAs with coaching, nutrition help, or tech tools that keep people on track.

Conclusion

This study from JAMA Network Open revealed a surprising truth: a lot of people start GLP-1 weight loss medications, but many stop within a year — and some return when the weight comes back.

It shows that even the best medications come with challenges, especially when it comes to side effects, money, and motivation.

The big takeaway? Sticking with treatment is tough. Support and access matter. And health journeys are rarely straight lines.

Explore More Medical Breakthroughs

For more insightful studies and information about exciting medical advancements, visit Explore More Medical Breakthroughs.

What This Article Covers

• How orforglipron works compared to injectables like Ozempic and Mounjaro
• The Phase 3 study design explained in kid-friendly terms
• Results: blood sugar control & weight-loss numbers unpacked
• Potential side effects and why they matter
• What we don’t know yet about long-term impact
• Who might benefit from a pill vs an injection
• What comes next in this treatment journey

Quick Summary (TL;DR)

Orforglipron is a once-daily pill that, in a 40-week Phase 3 trial, lowered A1C by up to 1.6 points and prompted an average 8% weight loss—similar to top injectable GLP-1 drugs—offering a possible needle-free diabetes treatment.

Why This Topic Matters Right Now

Millions of people around the world are struggling with Type 2 diabetes and the challenge of managing their weight. This condition can make life hard, as it affects energy levels, mood, and overall health. For many, injectable medications like Ozempic and Mounjaro have been a game-changer. However, they come with some downsides like needles, higher costs, and the need for special storage.

Imagine if you could get the same amazing results without the hassle of a needle! This is where orforglipron, a new weight loss pill, comes in. It could mean better health for many people, making it easier for them to manage their diabetes and lose weight.

What the Scientists Studied

Let’s think of your body like a washing machine. When you wash clothes, you want the right amount of water for them to get clean. A1C is like the water level in that washing machine. The higher your A1C, the more “dirty” your blood sugar is.

Researchers wanted to know if orforglipron could help lower A1C levels and help people lose weight. In their study, they tested three different sizes of orforglipron pills (3 mg, 12 mg, and 36 mg) against a dummy pill called a placebo, which does nothing at all. They included 559 adults with diabetes who hadn’t taken any medication for 90 days before the study started.

The study lasted 40 weeks, which is about nine months. During this time, scientists carefully monitored changes in A1C levels and participants' body weights. This way, they could see how well orforglipron worked compared to the placebo.

What They Found (And What It Means)

Lowering Blood Sugar Levels

One of the most exciting findings from the study was how much orforglipron helped lower A1C levels. The highest dose of the pill (36 mg) was able to cut A1C by 1.3 to 1.6 points. To put this into perspective, if someone had an A1C level of 8.0%, it could drop to around 6.4% to 6.7%. Think of this as fixing the water level in our washing machine from almost full (dirty clothes) to nearly perfect cleanliness.

Weight Loss

Participants in the study also saw some impressive weight loss results. On average, they lost about 7.9% of their body weight, which is roughly 16 pounds. This weight loss is similar to what people have experienced with injectable medications like Ozempic and Mounjaro.

Additionally, over 65% of the participants reached non-diabetic A1C levels, which is fantastic news! It means that many people were able to get their blood sugar levels back to a healthier range.

Side Effects

Like all medications, orforglipron had some side effects. The most common ones were nausea and diarrhea. These side effects were generally mild to moderate, and about 4% to 8% of participants decided to stop taking the medication because of them. This is important to consider because it shows that while the medication is effective, some people may not tolerate it well.

The First Small-Molecule Oral GLP-1 to Clear Phase 3

Another important point is that orforglipron is the first small-molecule oral GLP-1 medication to successfully pass through Phase 3 trials. This is a big step forward in diabetes treatment, as it could lead to more options for people who prefer taking a pill instead of using injections.

What This Doesn’t Mean (Keeping It Honest)

Not Yet Approved

While the results are promising, it’s important to remember that orforglipron has not yet been approved by healthcare regulators. The company plans to submit applications for weight loss approval by the end of 2025 and for diabetes treatment in 2026.

Long-Term Data Is Needed

We also don’t know how well orforglipron will work in the long term. The study only lasted 40 weeks, which isn’t enough time to understand how effective the pill will be after more extended use. Researchers still need to find out how it affects heart health or sleep quality over time.

Missing Head-to-Head Data

There is also a lack of direct comparisons between orforglipron and other medications like tirzepatide (Mounjaro/Zepbound). These comparisons are essential to determine how orforglipron stacks up against its competitors.

How This Might Help You (Without Making Claims)

If orforglipron is approved, it could provide a simpler, easier way to manage blood sugar and weight. Imagine taking a pill instead of dealing with needles! It would make things less complicated because you wouldn’t need to worry about storing the medication in the fridge or how to inject it.

This pill might also be more affordable than current medications, making it easier for more people to access modern diabetes care. For many, this could mean a healthier life with fewer barriers to getting the treatment they need.

Who Might Benefit from a Pill vs an Injection?

Different people have different preferences and needs when it comes to their medication. For some, a pill may be a better option than injections. Here are a few reasons why:

• Fear of Needles: Many people are scared of needles, and taking a pill might be much easier and less stressful.
• Convenience: Pills are usually easier to transport and don’t require special storage like injections do. You can carry them in your pocket or bag without worrying about keeping them cool.
• Cost: Pills can sometimes be cheaper to produce and distribute than injectable medications, which could lead to lower prices for patients.
• Lifestyle: Some people might find it easier to remember to take a pill once a day than to inject themselves regularly.

What Comes Next in This Treatment Journey

Additional Trials

Researchers are planning more trials to explore how orforglipron can help with other health issues, such as obesity, heart health, liver health, and even sleep apnea. These studies will be essential to understanding the full range of benefits that this new medication might offer.

Regulatory Submissions

As mentioned earlier, Eli Lilly is preparing to submit applications for regulatory approval in 2025 and 2026. This is an exciting step forward, as it could bring orforglipron to the market for many people who are looking for new treatment options.

Real-World Studies

Once orforglipron is approved, researchers will conduct real-world studies to see how well the pill works in everyday life compared to injectables. This will help determine how it fits into the routine of people living with diabetes and whether it truly offers a better experience.

Conclusion

In summary, orforglipron shows great promise as a convenient oral alternative to injectable GLP-1 medications. By significantly lowering blood sugar levels and body weight over 40 weeks, it could change the landscape of diabetes and weight-loss treatment for many people.

As we wait for more data and the approval process to unfold, it’s important to keep an eye on how this new medication may offer a simpler, needle-free option for managing health. With the potential to help millions of people better control their diabetes and manage their weight, orforglipron could be a true breakthrough in medical treatment.

Explore More Medical Breakthroughs

If you’re interested in learning more about the latest medical breakthroughs, check out other articles and resources that can help you stay informed about health and wellness. Knowledge is power, and understanding new developments can help you or your loved ones make better health decisions.

For additional information, visit Meridian Medical Centre.

What This Article Covers

Why people stop taking GLP-1 medications like semaglutide or tirzepatide – What happens after stopping these weight loss shots – How type 2 diabetes changes the restart rate – Surprising barriers like income and side effects – What this means for the future of weight loss treatment

Quick Summary (TL;DR)

Doctors studied how long people stayed on their GLP-1 weight loss meds—and found nearly half stopped in less than a year. Even more surprising? Most people never restarted, especially if they didn’t have diabetes. The reasons include side effects, money, and not losing enough weight.

Why This Topic Matters Right Now

If you’ve been hearing about weight loss shots like Ozempic®, Wegovy®, or Mounjaro®, you're not alone. These medications have made big promises—and even bigger headlines—for helping people lose weight fast.

But here’s the catch: many people stop using them.

That’s a big deal, because these medications aren’t just for weight loss. They help manage cravings, blood sugar, and long-term health risks.

So what’s happening? Are people losing motivation? Running out of money? Or are the side effects just too much?

This new study helps us understand the real story—straight from 2 million people who’ve used these GLP-1 meds.

What the Scientists Studied

Let’s imagine you run a giant library full of health records—millions of people, each with a story about their medications. That’s what the researchers did. They looked at data from over 2 million adults in the U.S. who started GLP-1 meds between 2014 and 2023.

They tracked:

• When each person started the medicine

• When (or if) they stopped

• And whether they ever started again

To keep things fair, they only looked at people with overweight or obesity who were taking the meds for weight loss—not just for blood sugar or diabetes alone.

They also looked at differences between people with and without type 2 diabetes, to see how that condition affected the likelihood of stopping or restarting.

What They Found (And What It Means)

Here’s the big headline:

Nearly 48% of people stopped their GLP-1 med within one year.

And here’s the even more surprising part:

Only 2 in 10 restarted it again.
That means once people stop, they mostly don’t go back.

Who Was Most Likely to Stop?

• People without type 2 diabetes were more likely to stop than those with it

• Those who lost little to no weight early on were more likely to quit

• People with lower income stopped more often—probably because of cost

• Common side effects like nausea and vomiting pushed some to quit early

Who Was Most Likely to Restart?

If someone had type 2 diabetes, they were much more likely to go back on the medication. Why?

Because these meds don’t just help with weight. They also control blood sugar—which is critical for people with diabetes.

In contrast, people who took it only for weight loss had fewer clear health markers that “forced” them to restart. They may not have seen the weight return fast enough—or simply didn’t feel worse after stopping.

What This Doesn’t Mean (Keeping It Honest)

This study doesn’t say that the medications don’t work. In fact, many people did lose weight—especially if they stayed on the drug.

It also doesn’t mean people can’t lose weight without meds.

But it does mean that:

• Taking GLP-1 meds long-term is harder than we thought

• Quitting doesn’t always mean failure—just that life (or costs) got in the way

• Results may vary widely depending on health conditions, goals, or resources

How This Might Help You (Without Making Claims)

If you’re thinking about starting a weight loss medication, or if you’re already on one, this study is a helpful reality check.

It shows that:

• You’re not alone if the side effects bother you

• It’s common to hit pause on the journey

• Having a plan before stopping can help you feel more in control

It might also help you talk to your doctor about what to expect—and how to prepare if the cost becomes a barrier.

Where the Science Goes Next

This study raises some big questions:

• Should people take GLP-1s forever? Or can short bursts help?

• What are the long-term effects of stopping and restarting?

• Could there be better support systems—like coaching or nutrition guidance—to help people stay consistent?

• And how can we make these medications more affordable for people who benefit the most?

Researchers are now looking into how to make these treatments last—and how to give people the tools to succeed, even after they stop.

Conclusion

Half of people on GLP-1 meds like Ozempic or Wegovy stop within a year. And most never restart.

For those with type 2 diabetes, restarting is more common—probably because the meds control more than just weight. But for people taking them purely to slim down, the journey is trickier.

Whether it’s side effects, cost, or slow results, many hit a wall.

But understanding why people stop is the first step to helping more succeed.

Explore More Medical Breakthroughs

(https://meridianmedicalcentre.com)